J A Ramirez1, J Bordon. 1. Division of Infectious Diseases, Department of Medicine, University of Louisville, Louisville, KY 40292, USA. j.ramirez@louisville.edu
Abstract
BACKGROUND: The identification of Streptococcus pneumoniae bacteremia in hospitalized patients with community-acquired pneumonia is considered by some investigators to be an exclusion criterion for early switch from intravenous to oral therapy. OBJECTIVE: To determine whether the switch from intravenous to oral therapy in such patients, once the bx;1patient reaches clinical stability, is associated with poor clinical outcome. METHODS: The medical records of 400 patients with community-acquired pneumonia hospitalized at the Veterans Affairs Medical Center of Louisville (Louisville, Ky) were reviewed to identify patients with bacteremic S pneumoniae. Four criteria were used to define when a patient reached clinical stability and should be considered a candidate for switch therapy: (1) cough and shortness of breath are improving, (2) patient is afebrile for at least 8 hours, (3) white blood cell count is normalizing, and (4) oral intake and gastrointestinal tract absorption are adequate. RESULTS: A total of 36 bacteremic patients were identified. No clinical failures occurred in 18 patients who reached clinical stability and were switched to oral therapy or in 7 patients who reached clinical stability and continued intravenous therapy. Clinical failures (5 deaths) occurred in the group of 11 patients who did not reach clinical stability. CONCLUSION: Once a hospitalized patient with community-acquired pneumonia reaches clinical stability, it is safe to switch from intravenous to oral antibiotics even if bacteremia caused by S pneumoniae was initially documented.
BACKGROUND: The identification of Streptococcus pneumoniae bacteremia in hospitalized patients with community-acquired pneumonia is considered by some investigators to be an exclusion criterion for early switch from intravenous to oral therapy. OBJECTIVE: To determine whether the switch from intravenous to oral therapy in such patients, once the bx;1patient reaches clinical stability, is associated with poor clinical outcome. METHODS: The medical records of 400 patients with community-acquired pneumonia hospitalized at the Veterans Affairs Medical Center of Louisville (Louisville, Ky) were reviewed to identify patients with bacteremic S pneumoniae. Four criteria were used to define when a patient reached clinical stability and should be considered a candidate for switch therapy: (1) cough and shortness of breath are improving, (2) patient is afebrile for at least 8 hours, (3) white blood cell count is normalizing, and (4) oral intake and gastrointestinal tract absorption are adequate. RESULTS: A total of 36 bacteremic patients were identified. No clinical failures occurred in 18 patients who reached clinical stability and were switched to oral therapy or in 7 patients who reached clinical stability and continued intravenous therapy. Clinical failures (5 deaths) occurred in the group of 11 patients who did not reach clinical stability. CONCLUSION: Once a hospitalized patient with community-acquired pneumonia reaches clinical stability, it is safe to switch from intravenous to oral antibiotics even if bacteremia caused by S pneumoniae was initially documented.
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: M F Engel; A H W Bruns; M E J L Hulscher; C A J M Gaillard; S U C Sankatsing; F Teding van Berkhout; M H Emmelot-Vonk; E M Kuck; M H M Steeghs; J H den Breeijen; R K Stellato; A I M Hoepelman; J J Oosterheert Journal: Eur J Clin Microbiol Infect Dis Date: 2014-05-26 Impact factor: 3.267
Authors: A Mykietiuk; J Carratalà; A Domínguez; A Manzur; N Fernández-Sabé; J Dorca; F Tubau; F Manresa; F Gudiol Journal: Eur J Clin Microbiol Infect Dis Date: 2006-07 Impact factor: 3.267
Authors: Matthew J Labreche; Grace C Lee; Russell T Attridge; Eric M Mortensen; Jim Koeller; Liem C Du; Natalie R Nyren; Lucina B Treviño; Sylvia B Treviño; Joel Peña; Michael W Mann; Abilio Muñoz; Yolanda Marcos; Guillermo Rocha; Stella Koretsky; Sandra Esparza; Mitchell Finnie; Steven D Dallas; Michael L Parchman; Christopher R Frei Journal: J Am Board Fam Med Date: 2013 Sep-Oct Impact factor: 2.657
Authors: J M Bordon; R Fernandez-Botran; T L Wiemken; P Peyrani; S M Uriarte; F W Arnold; L Rodriquez-Hernandez; M J Rane; R R Kelley; L E Binford; S Uppatla; R Cavallazzi; F Blasi; S Aliberti; M I Restrepo; S Fazeli; A Mathur; M Rahmani; K Ayesu; J Ramirez Journal: Infection Date: 2015-09-30 Impact factor: 3.553